Valneva SE

Regulatory Filings • Mar 24, 2016

Valneva to present at the 16th World Vaccine Congress in Washington D.C.

Lyon (France), March 24, 2016 Valneva SE ("Valneva" or "the Company"), a leading pure play vaccine company, announced today that it will be holding two presentations on Lyme disease and hospital-acquired infections on March 30, 2016 at the 16th World Vaccine Congress in Washington DC. Over 600 vaccine specialists will converge to the event.

Valneva's CEO Thomas Lingelbach will join Prof Stanley A. Plotkin, Emeritus Professor, University of Pennsylvania, in a presentation focusing on the necessity of developing a vaccine for Lyme disease. The presentation will include an update on Valneva's

development strategy for its Lyme disease vaccine VLA 15 which is expected to enter Phase I clinical trial in the second half of 2016. Pre-clinical data showed that VLA 15 can provide protection against the majority of Borrelia species pathogenic for humans¹ .

Valneva will also present on the necessity of prophylactic vaccinations against hospital acquired infections, also known as nosocomial infections, showing that they are becoming a growing threat to patients' health. Valneva currently develops vaccine candidates against Pseudomnas aeruginosa , a highly-resistant bacterium responsible

for approximately 51,000² healthcare-associated infections annually, and Clos?D v espC /P BDC BT / 0 0 1 348.1 398.5 Tm [(f73 -ET
)-26(ap3fs c

About Valneva SE

Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

prevention of Japanese Encephalitis (IXIARO® /JESPECT® ) and the second (DUKORAL® ) indicated for the prevention of Cholera and, in some countries, prevention of diarrhea caused by LT

performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccine.F-144.4-207(ot8)6expected